Bisphosphonate label now includes precaution about osteonecrosis

Article

Revisions have been made to the precautions and adverse reactions sections of the label for the bisphosphonate zoledronic acid (Zometa).

Revisions have been made to the precautions and adverse reactions sections of the label for the bisphosphonate zoledronic acid (Zometa).

Among patients with concomitant risk factors (eg, cancer, chemotherapy, corticosteroids, poor oral hygiene), a dental examination with appropriate preventative dentistry should be considered before treatment with bisphosphonates, according to a letter from the drug's manufacturer, Novartis.

The FDA and Novartis notified health care professionals of spontaneous reports of osteonecrosis of the jaw, mainly of cancer patients, who have received bisphosphonates as a component of their therapy. Zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy and for the treatment of patients with multiple myeloma and those with documented bone metastases from solid tumors, including prostate cancer, in conjunction with standard antineoplastic therapy.

Related Videos
Vikas Desai, MD, answers a question during a Zoom video interview
Bree Duncan, RN, BSN, answers a question during a Zoom video interview
3d rendered illustration of bladder cancer | Image Credit: © SciePro - stock.adobe.com
Roger R. Dmochowski, MD, MMHC, FACS, answers a question during a Zoom video interview
Doctor holding patient's hands | Image Credit: © bongkarn - stock.adobe.com
Roger R. Dmochowski, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.